Scientist III, Biological Science

Deciphera, a member of Ono Pharmaceutical Co., Ltd., is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines and providing hope to people living with cancer, neurologic and autoimmune disease. Deciphera isleveragingits proprietary switch-control kinase inhibitor platform and deepexpertisein kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from Deciphera’splatform in clinical studies, QINLOCK® (ripretinib) is Deciphera’sswitch-control kinase inhibitor approved in many countries including the European Union and the United States for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

ROMVIMZA® (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatictenosynovialgiant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity, and in the European Union for adult patients with TGCT associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability.

The spirit of collaboration that has brought medications to life continues to guide how weoperate, grow, and discover new breakthroughs. We cultivate an inclusive culture that values curiosity, creativity, and shared accountability—empowering individuals to challenge the unknown together.

Deciphera offers competitive compensation, including equity-based compensation,and a comprehensive benefits package that includes medical, dental, vision, 401(k) retirement plan, lifeinsuranceand a flexible spending account for either health care and/or dependent care.

We are seeking a motivated Scientist III to join our drug discovery team and help advance innovative small molecule programs through high-quality assay development, screening, and automation-enabled workflows. In this role, you will independently design, execute, optimize, and interpret biochemical and cell-based assays, including high-throughput screening assays in 384- and 1536-well formats. You will partner closely with biologists, biochemists, medicinal chemists, and automation teams to generate decision-making data, troubleshoot complex workflows, and apply new technologies that improve assay performance and accelerate the Design, Make, Test, Analyze (DMTA) cycle.

This is an exciting opportunity for a hands-on scientist who enjoys building robust assays, applying enzyme kinetics expertise, and leveraging lab automation platforms such as the Agilent BRAVO, Beckman ECHO, Formulatrix Mantis, and Certus Flex to support fast-paced discovery research.

• Develop, optimize, and execute high-throughput screening assays in 384- and 1536-well formats, including both cell-free and cell-based assay systems.
• Apply knowledge of enzyme kinetics to design experiments, interpret assay performance, and support mechanism-of-action studies for small molecules.
• Operate, program, and troubleshoot liquid handling and automation platforms, including systems such as Agilent BRAVO, Beckman ECHO, Formulatrix Mantis, and Certus Flex.
• Evaluate and implement lab automation technologies that improve assay workflows, increase throughput, and reduce DMTA cycle time.
• Maintain and calibrate laboratory equipment to support experimental precision, reproducibility, and operational excellence.
• Manage CRO studies and external collaborations as needed to support project deliverables.
• Follow all safety, quality control, and documentation procedures.

• Analyze experimental results, assess assay quality, and summarize key findings to inform program decisions.
• Document experiments, protocols, and data clearly in electronic notebooks, LIMS, and other required systems.
• Prepare reports, presentations, and data summaries for internal teams and cross-functional stakeholders.